PubRank

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

Clinical Trial ID NCT01096602

PubWeight™ 25.20‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01096602

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
2 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
3 Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012 1.51
4 Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014 1.24
5 The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014 1.18
6 Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011 1.16
7 Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs 2014 0.99
8 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
9 Dendritic cell-based immunotherapy for myeloid leukemias. Front Immunol 2013 0.90
10 Targeting the innate immune system as immunotherapy for acute myeloid leukemia. Front Oncol 2015 0.89
11 Evaluation of current cancer immunotherapy: hemato-oncology. Cancer J 2011 0.88
12 Enhancement of dendritic cells as vaccines for cancer. Immunotherapy 2010 0.86
13 Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta 2015 0.86
14 Optimizing dendritic cell-based approaches for cancer immunotherapy. Yale J Biol Med 2014 0.85
15 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
16 The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity. Blood Cancer J 2014 0.84
17 New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res 2014 0.83
18 Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015 0.82
19 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
20 Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opin Biol Ther 2015 0.79
21 Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic). Ther Adv Hematol 2016 0.79
22 Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology 2015 0.78
23 A quantitative analysis of therapeutic cancer vaccines in phase 2 or phase 3 trial. J Immunother Cancer 2015 0.76
24 Immunomodulatory drugs II: Immune Checkpoint Agents in Acute Leukemia. Curr Drug Targets 2015 0.75
Next 100